
Faes Farma S.A (FAE) | Financial Analysis & Statements
Faes Farma S.A. | Large-cap | Healthcare
Faes Farma S.A. | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2024Income Metrics
Revenue
134.6M
Gross Profit
93.3M
69.26%
Operating Income
42.6M
31.63%
Net Income
27.9M
20.69%
Balance Sheet Metrics
Total Assets
853.1M
Total Liabilities
126.5M
Shareholders Equity
726.6M
Debt to Equity
0.17
Cash Flow Metrics
Revenue & Profitability Trend
Faes Farma S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 493.6M | 451.2M | 438.8M | 398.6M | 380.2M |
Cost of Goods Sold | 167.1M | 154.0M | 156.7M | 146.2M | 140.4M |
Gross Profit | 326.5M | 297.1M | 282.0M | 252.4M | 239.8M |
Gross Margin % | 66.1% | 65.9% | 64.3% | 63.3% | 63.1% |
Operating Expenses | |||||
Research & Development | - | 5.2M | 3.7M | 3.9M | 3.2M |
Selling, General & Administrative | - | 57.4M | 52.5M | 49.3M | 41.2M |
Other Operating Expenses | 109.2M | 35.8M | 35.0M | 27.4M | 34.9M |
Total Operating Expenses | 109.2M | 98.4M | 91.2M | 80.6M | 79.4M |
Operating Income | 108.5M | 103.7M | 102.2M | 97.8M | 92.6M |
Operating Margin % | 22.0% | 23.0% | 23.3% | 24.5% | 24.3% |
Non-Operating Items | |||||
Interest Income | 1.7M | 1.1M | 253.0K | 23.0K | 156.0K |
Interest Expense | 433.0K | 383.0K | 263.0K | 216.0K | 266.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 107.6M | 102.9M | 101.4M | 93.0M | 84.9M |
Income Tax | -3.5M | 11.2M | 12.0M | 10.5M | 11.5M |
Effective Tax Rate % | -3.3% | 10.8% | 11.8% | 11.3% | 13.6% |
Net Income | 111.1M | 91.7M | 89.4M | 82.4M | 73.4M |
Net Margin % | 22.5% | 20.3% | 20.4% | 20.7% | 19.3% |
Key Metrics | |||||
EBITDA | 129.8M | 123.3M | 121.3M | 114.7M | 105.6M |
EPS (Basic) | €0.36 | €0.30 | €0.28 | €0.27 | €0.25 |
EPS (Diluted) | €0.36 | €0.30 | €0.28 | €0.26 | €0.24 |
Basic Shares Outstanding | 309333333 | 306340000 | 317403692 | 302670130 | 290618676 |
Diluted Shares Outstanding | 309333333 | 306340000 | 317403692 | 302670130 | 290618676 |
Income Statement Trend
Faes Farma S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 64.2M | 34.6M | 66.4M | 70.3M | 91.2M |
Short-term Investments | 7.9M | 13.1M | 17.7M | 3.2M | 1.9M |
Accounts Receivable | 111.0M | 104.1M | 101.6M | 102.1M | 99.2M |
Inventory | 142.5M | 128.7M | 114.0M | 106.5M | 91.1M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 333.7M | 290.3M | 313.2M | 293.7M | 290.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 300.9M | 61.5M | 59.6M | 2.2M | 2.4M |
Goodwill | 240.7M | 240.3M | 230.5M | 236.1M | 218.2M |
Intangible Assets | 127.6M | 128.1M | 126.9M | 129.4M | 112.9M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | 4.0K | - |
Total Non-Current Assets | 519.4M | 485.7M | 413.9M | 351.4M | 291.5M |
Total Assets | 853.1M | 776.0M | 727.2M | 645.1M | 581.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 46.8M | 35.4M | 36.6M | 37.9M | 42.0M |
Short-term Debt | 2.0M | 19.5M | 28.3M | 14.3M | 12.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | 59.0K |
Total Current Liabilities | 103.5M | 86.8M | 94.4M | 79.3M | 84.7M |
Non-Current Liabilities | |||||
Long-term Debt | - | 4.4M | 4.4M | 2.2M | 1.6M |
Deferred Tax Liabilities | 15.6M | 16.9M | 21.1M | 21.7M | 17.4M |
Other Non-Current Liabilities | - | 241.0K | 35.0K | 157.0K | 687.0K |
Total Non-Current Liabilities | 23.0M | 25.9M | 30.3M | 28.5M | 24.0M |
Total Liabilities | 126.5M | 112.7M | 124.7M | 107.8M | 108.6M |
Equity | |||||
Common Stock | 31.6M | 31.6M | 31.1M | 29.7M | 28.5M |
Retained Earnings | 209.0M | 165.8M | 147.5M | 127.0M | 104.3M |
Treasury Stock | 11.0M | 11.0M | 5.3M | 5.3M | 5.3M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 726.6M | 663.3M | 602.4M | 537.3M | 472.9M |
Key Metrics | |||||
Total Debt | 2.0M | 23.9M | 32.7M | 16.4M | 13.9M |
Working Capital | 230.3M | 203.5M | 218.8M | 214.4M | 205.3M |
Balance Sheet Composition
Faes Farma S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 107.6M | 91.7M | 89.4M | 82.4M | 73.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | 774.0K | 146.0K | 0 | - |
Working Capital Changes | 0 | -12.3M | -9.9M | -14.7M | -32.2M |
Operating Cash Flow | 114.2M | 79.6M | 79.6M | 67.9M | 41.3M |
Investing Activities | |||||
Capital Expenditures | -39.5M | -95.8M | -68.0M | -51.1M | -19.8M |
Acquisitions | - | -4.5M | 0 | -22.6M | 0 |
Investment Purchases | - | -8.8M | -21.5M | -1.9M | -600.0K |
Investment Sales | 13.1M | 18.2M | 2.8M | - | - |
Investing Cash Flow | -34.2M | -90.9M | -86.7M | -75.6M | -20.4M |
Financing Activities | |||||
Share Repurchases | - | -17.7M | 0 | 0 | -92.0K |
Dividends Paid | -48.2M | -14.6M | -18.1M | -13.7M | -11.5M |
Debt Issuance | - | 260.0K | 2.3M | 0 | 458.0K |
Debt Repayment | -3.5M | -3.3M | -2.6M | -3.4M | -946.0K |
Financing Cash Flow | -51.7M | -35.4M | -18.5M | -19.1M | -13.9M |
Free Cash Flow | 75.9M | -1.2M | 26.1M | 20.2M | 52.8M |
Net Change in Cash | 28.4M | -46.7M | -25.6M | -26.7M | 6.9M |
Cash Flow Trend
Faes Farma S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.41
Forward P/E
14.55
Price to Book
1.80
Price to Sales
2.42
PEG Ratio
14.55
Profitability Ratios
Profit Margin
19.37%
Operating Margin
18.19%
Return on Equity
14.83%
Return on Assets
6.92%
Financial Health
Current Ratio
2.29
Debt to Equity
11.48
Beta
0.33
Per Share Data
EPS (TTM)
€0.34
Book Value per Share
€2.34
Revenue per Share
€1.75
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
fae | 1.3B | 12.41 | 1.80 | 14.83% | 19.37% | 11.48 |
Laboratorios | 2.7B | 20.56 | 4.83 | 25.01% | 17.66% | 22.50 |
Almirall S.A | 2.2B | 102.60 | 1.51 | 1.45% | 2.02% | 26.47 |
Laboratorio Reig | 240.1M | 42.14 | 1.10 | 3.03% | 1.89% | 31.04 |
Labiana Health S.A | 27.9M | - | 5.80 | 6.92% | 0.38% | 1,378.08 |
Grifols, S.A | 7.8B | 29.19 | 1.69 | 4.99% | 4.00% | 126.87 |
Financial data is updated regularly. All figures are in the company's reporting currency.